Table 3 Combination therapy of KRAS (G12C) inhibitors in clinical trials
From: KRAS mutation: from undruggable to druggable in cancer
ClinicalTrials.gov registration | Drug | Disease setting | Study phase | Recruitment status |
|---|---|---|---|---|
Combined with chemotherapy | ||||
NCT04303780 | AMG510 Docetaxel | NSCLC | III | Recruiting |
NCT04185883 | AMG510 Docetaxel | Advanced NSCLC | I b | Recruiting |
NCT04165031 | LY3499446 Docetaxel | Solid tumours | I/II | Terminated |
NCT04685135 | MRTX849 Docetaxel | Metastatic NSCLC | III | Recruiting |
Combined with targeted therapy | ||||
NCT04185883 | AMG510 Erlotinib | Solid tumours | I b | Recruiting |
NCT04185883 | AMG510 TNO155 | Solid tumours | I b | Recruiting |
NCT04185883 | AMG510 Selumetinib | Solid tumours | I b | Recruiting |
NCT04185883 | AMG510 Everolimus | Solid tumours | I b | Recruiting |
NCT03785249 | MRTX849 Afatinib | NSCLC | I/II | Recruiting |
NCT03785249 | MRTX849 Cetuximab | Solid tumours | I/II | Recruiting |
NCT04793958 | MRTX849 Cetuximab | Metastatic CRC | III | Recruiting |
NCT04330664 | MRTX849 TNO155 | NSCLC | I/II | Recruiting |
NCT04165031 | LY3499446 Abemaciclib | Advanced NSCLC | I/II | Terminated |
NCT04165031 | LY3499446 Erlotinib | Advanced NSCLC | I/II | Active not recruiting |
NCT04449874 | GDC-6036 Erlotinib | Solid tumours | I a/I b | Recruiting |
NCT04449874 | GDC-6036 Cetuximab | Solid tumours | I a/I b | Recruiting |
NCT04449874 | GDC-6036 Bevacizumab | Solid tumours | I a/I b | Recruiting |
Combined with immune therapy | ||||
NCT03600883 | AMG510 Pembrolizumab | NSCLC | II | Recruiting |
NCT03600883 | AMG510 Atezolizumab | NSCLC | II | Recruiting |
NCT03785249 | MRTX849 Pembrolizumab | NSCLC | I/II | Recruiting |
NCT04613596 | MRTX849 Pembrolizumab | NSCLC | II | Not yet recruiting |
NCT04449874 | GDC-6036 Atezolizumab | Solid tumours | I a/I b | Recruiting |
